GlassScriptPhysician profile
Amiad Harow
NPI 1588293328
$6,584.59
in general payments reported to CMS, 2019-2025
35 companies · $2,259 in 2025
The $2,259 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,122 · 2024: $3,204 · 2025: $2,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,564 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,564.37 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $964.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $924.18 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $698.80 | 2023-2025 | Farxiga, Breztri |
| Amgen INC. | $542.83 | 2023-2025 | Repatha, Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.93 | 2023-2025 | Jardiance |
| Pfizer INC. | $469.83 | 2023-2025 | |
| Exact Sciences Corporation | $270.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $247.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $187.78 | 2023-2025 | Verquvo, Capvaxive, Lagevrio |
| Esperion Therapeutics, INC. | $178.87 | 2024-2025 | Nexletol |
| Abbott Laboratories | $145.38 | 2024-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $139.11 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $138.02 | 2023-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $133.49 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $128.79 | 2024-2025 | Onpattro, Amvuttra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $99.58 | 2024-2025 | Inspire |
| Corcept Therapeutics | $91.27 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $75.57 | 2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $71.60 | 2023-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $67.45 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $53.98 | 2025 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Scpharmaceuticals INC. | $49.27 | 2023-2025 | |
| Ardelyx, INC. | $48.74 | 2024 | Ibsrela |
| Currax Pharmaceuticals LLC | $42.76 | 2024-2025 | Contrave |
| Medtronic, INC. | $41.40 | 2024 | Corevalve Evolut R |
| Scilex Pharmaceuticals INC. | $38.18 | 2023-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.66 | 2023-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.11 | 2025 | Caplyta |
| Lundbeck LLC | $29.05 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $25.00 | 2025 | Gvoke Hypopen |
| Viiv Healthcare Company | $21.88 | 2023 | Apretude |
| Gilead Sciences, INC. | $21.26 | 2025 | |
| Intra-Sana Laboratories | $17.83 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Mannkind Corporation | $16.27 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.62 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amiad Harow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.